-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Maintains Buy on BlossomHill Therapeutics, Raises Price Target to $40

Benzinga·09/21/2026 13:03:29
Listen to the news
Guggenheim analyst Michael Schmitz maintains BlossomHill Therapeutics (NASDAQ:BLSM) with a Buy and raises the price target from $30 to $40.